Lavipharm S.A. Stock

LAVI

GRS246003008

Pharmaceuticals

Market Closed - Athens S.E. 01:14:19 17/10/26 am AEDT			5-day change	1st Jan Change
1.508 ^EUR	-0.13%		-0.13%	+55.46%

18/09	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI

Lavipharm SA is a Greece-based pharmaceutical and healthcare company engaged in the research and development of drug delivery solutions and the commercialisation of pharmaceutical, over-the-counter (OTC) and related healthcare products. It is active in the provision of prescription medicines, OTC products and food supplements, supported by integrated activities across research and development, manufacturing and commercial operations. It maintains a portfolio focused primarily on therapeutic areas including cardiology, central nervous system disorders, urology, oncology and chronic pain, supplying solutions designed for healthcare professionals and patients. The Company operates in both domestic and international markets and combines product development capabilities with market access and distribution activities, while acting as the parent entity of the Lavipharm Group through which its broader operations are conducted.

Employees

306

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
16/10/26	EUR 1.508	-0.13%	6,052
15/10/26	EUR 1.510	+0.13%	31,861
14/10/26	EUR 1.508	+0.13%	42,915
13/10/26	EUR 1.506	-0.92%	46,701
12/10/26	EUR 1.520	+0.66%	39,045

Delayed Quote Athens S.E.

Rankings

Rankings

Currency / Forex

Commodities

Cryptocurrencies

Interest Rates

Stock Market
Stocks
LAVI Stock

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	258M 290M 239M 217M 410M 27.5B 416M 2.87B 1.12B 14.35B 1.09B 1.06B 45.74B	P/E 2024	14.9x	P/E 2025	27.9x
Enterprise Value	284M 320M 263M 240M 452M 30.34B 460M 3.17B 1.24B 15.84B 1.2B 1.17B 50.48B	EV / Sales 2024	3.07x	EV / Sales 2025	3.04x
Free-Float	38.91%	Yield 2024	2.52%	Yield 2025	2.06%

18/09	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
25/06	Lavipharm S.A. announces Annual dividend, payable on July 24, 2026	CI
29/05	Lavipharm Q1 earnings before tax from continuing operations EUR1.41 million, up 28.6% Y/Y	RE
29/05	Lavipharm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
09/04	Lavipharm to acquire Durogesic pain patch rights from Janssen for $12.0 million	RE
20/03	Lavipharm SA FY 2025 earnings after tax EUR 6.0 million versus EUR 9.0 million year ago	RE
20/03	Lavipharm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
18/11	Lavipharm 9-month net profit down to EUR 3.5 million	RE
19/09/25	Lavipharm H1 adjusted EBITDA at EUR 7.7 million, up 29.4% Y/Y	RE
18/09/25	Lavipharm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
03/07/25	Lavipharm S.A. announces Annual dividend, payable on July 24, 2025	CI
16/05/25	Lavipharm Q1 Net Profit At EUR 1.6 Million, Up 46.8% YoY	RE
15/04/25	Lavipharm And Tikun Olam Europe Launch Joint Telemedicine Company	RE

01/10	Lavipharm S A : Announcement	PU
03/09	Lavipharm S A : Announcement Appointment of Chief Manufacturing & Operations Officer	PU
11/06	Lavipharm S A : Announcement Appointment of Chief Quality Officer	PU
22/05	Lavipharm S A : IMPORTANT CORPORATE EVENTS	PU
07/11	Lavipharm S A : OTHER ANNOUNCEMENTS	PU

1 day	-0.13%
1 week	-0.13%
Current month	-4.19%
1 month	-5.16%
3 months	+2.31%
6 months	+8.33%
Current year	+55.46%

1 week	1.48	1.56
1 month	1.46	1.62
Current year	0.94	1.74
1 year	0.78	1.74
3 years	0.58	1.74
5 years	0.35	2.22
10 years	0.21	2.22

Lavipharm S.A. Stock

Stocks

LAVI

GRS246003008

Pharmaceuticals

Valuation: Lavipharm S.A.

Chart: Lavipharm S.A.

Latest news: Lavipharm S.A.

Press Releases: Lavipharm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Lavipharm S.A.

Latest insider transactions

Generic Pharmaceuticals

Financials

Company Profile

Quotes

Manager	Title	Age	Since
Vassilis Baloumis DFI	Director of Finance/CFO	-	01/12/2021
Ligia Panaitescu CTO	Chief Tech/Sci/R&D Officer	-	-
Eleana Nikolopoulou CMP	Compliance Officer	-	-

Director	Title	Age	Since
Venetsiana-Loukia Lavida BRD	Director/Board Member	-	-
Christos Panagiotis Diamantopoulos BRD	Director/Board Member	76	-
Minas G. Tanes CHM	Chairman	86	01/01/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/2/25	Vassilis Baloumis	Buy	Chief Financial Officer	20,000	0.0119%
27/5/23	Thomas Tseronis	Sell		35,434	0.0189%
28/3/23	Vassilis Baloumis	Buy	Chief Financial Officer	23,455	0.0125%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
LAVIPHARM S.A.	-0.13%	-0.13%	+93.09%	+151.33%	290M
ELI LILLY AND COMPANY	+0.43%	+6.59%	+53.41%	+103.85%	1,120B
JOHNSON & JOHNSON	+0.90%	-2.25%	+33.02%	+62.23%	616B
ABBVIE INC.	+0.71%	+3.24%	+25.81%	+93.86%	504B
ROCHE HOLDING AG	-0.13%	+5.98%	+32.91%	+50.39%	367B
MERCK & CO., INC.	+0.52%	+0.24%	+73.92%	+40.15%	360B
NOVARTIS AG	-0.95%	+4.70%	+19.51%	+43.00%	288B
ASTRAZENECA PLC	-1.98%	+3.73%	-0.86%	+13.43%	258B
AMGEN INC.	-0.35%	+4.25%	+46.21%	+50.76%	234B
GILEAD SCIENCES, INC.	-0.75%	+3.32%	+32.53%	+97.21%	194B
Average	-0.17%	+3.24%	+40.95%	+70.62%	394.12B
Weighted average by Cap.	+0.13%	+3.83%	+39.18%	+71.44%

	2024	2025
Net sales	52.95M 59.56M 49.07M 44.65M 84.25M 5.65B 85.6M 590M 231M 2.95B 224M 219M 9.4B	62.58M 70.41M 58.01M 52.78M 99.59M 6.68B 101M 697M 273M 3.49B 264M 259M 11.12B
Net income	8.98M 10.1M 8.33M 7.57M 14.29M 959M 14.52M 100M 39.24M 500M 37.92M 37.12M 1.6B	5.99M 6.73M 5.55M 5.05M 9.53M 639M 9.68M 66.69M 26.15M 334M 25.27M 24.74M 1.06B
Net Debt	28.34M 31.88M 26.26M 23.89M 45.09M 3.03B 45.81M 316M 124M 1.58B 120M 117M 5.03B	26.67M 30.01M 24.72M 22.49M 42.45M 2.85B 43.13M 297M 117M 1.49B 113M 110M 4.74B